{"id":"NCT05590403","sponsor":"GlaxoSmithKline","briefTitle":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","officialTitle":"A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults â‰¥60 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-28","primaryCompletion":"2023-03-13","completion":"2024-02-12","firstPosted":"2022-10-21","resultsPosted":"2024-05-21","lastUpdate":"2025-03-06"},"enrollment":1544,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RSVPreF3 OA investigational vaccine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Adults HA-RSV Group","type":"EXPERIMENTAL"},{"label":"Adults HA-Placebo Group","type":"PLACEBO_COMPARATOR"},{"label":"Adults AIR-RSV Group","type":"EXPERIMENTAL"},{"label":"Adults AIR-Placebo Group","type":"PLACEBO_COMPARATOR"},{"label":"OA-RSV Group","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults \\>=60 YOA","primaryOutcome":{"measure":"RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group","timeFrame":"At 1 month after the RSVPreF3 OA vaccine administration (Day 31)","effectByArm":[{"arm":"Adults HA-RSV Group","deltaMin":7906,"sd":null},{"arm":"OA-RSV Group","deltaMin":7518.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["39099093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":383},"commonTop":["Administration site pain","Fatigue","Myalgia","Headache","Arthralgia"]}}